Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin

Detalhes bibliográficos
Autor(a) principal: Fuchs, Beth Burgwyn
Data de Publicação: 2016
Outros Autores: RajaMuthiah, Rajmohan, Souza, Ana Carolina Remondi [UNIFESP], Eatemadpour, Soraya, Rossoni, Rodnei Dennis, Santos, Daniel Assis, Junqueira, Juliana C., Rice, Louis B., Mylonakis, Eleftherios
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://repositorio.unifesp.br/handle/11600/49616
https://doi.org/10.4155/fmc.15.182
Resumo: Background: We identified auranofin as an antimicrobial compound utilizing a high-throughput screen using a Caenorhabditis elegans-Staphylococcus aureus infection model. Results/methodology: Treatment of infected nematodes with auranofin resulted in a prolonged survival rate of 95%, reached with 0.78 mu g/ml. Further investigation of the antimicrobial activity of auranofin found inhibition against S. aureus, Enterococcus faecium and Enterococcus faecalis. Importantly, the fungal pathogens Cryptococcus neoformans was also effectively inhibited with an MIC at 0.5 mu g/ml. Auranofin appears to target the thioredoxin system. Conclusion: This work provides extensive additional data on the antibacterial effects of auranofin that includes both reference and clinical isolates and reports a novel inhibition of fungal pathogens by this compound.
id UFSP_8fc37e61a04e44561805f3acf5a83628
oai_identifier_str oai:repositorio.unifesp.br:11600/49616
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Fuchs, Beth BurgwynRajaMuthiah, RajmohanSouza, Ana Carolina Remondi [UNIFESP]Eatemadpour, SorayaRossoni, Rodnei DennisSantos, Daniel AssisJunqueira, Juliana C.Rice, Louis B.Mylonakis, Eleftherios2019-01-21T10:30:09Z2019-01-21T10:30:09Z2016Future Medicinal Chemistry. London, v. 8, n. 2, p. 117-132, 2016.1756-8919http://repositorio.unifesp.br/handle/11600/49616https://doi.org/10.4155/fmc.15.18210.4155/fmc.15.182WOS:000369950000004Background: We identified auranofin as an antimicrobial compound utilizing a high-throughput screen using a Caenorhabditis elegans-Staphylococcus aureus infection model. Results/methodology: Treatment of infected nematodes with auranofin resulted in a prolonged survival rate of 95%, reached with 0.78 mu g/ml. Further investigation of the antimicrobial activity of auranofin found inhibition against S. aureus, Enterococcus faecium and Enterococcus faecalis. Importantly, the fungal pathogens Cryptococcus neoformans was also effectively inhibited with an MIC at 0.5 mu g/ml. Auranofin appears to target the thioredoxin system. Conclusion: This work provides extensive additional data on the antibacterial effects of auranofin that includes both reference and clinical isolates and reports a novel inhibition of fungal pathogens by this compound.COBRE-Immune-based intervention against infectious diseases pilot grantBrown University Dean's Emerging Areas of New Science awardNIHBrown-Brazil InitiativeRhode Island Hospital, Alpert Medical School & Brown University, Providence, RI 02903, USAEscola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, BrazilDepartment of Biosciences & Oral Diagnosis, Univ Estadual Paulista/UNESP, São José dos Campos, SP 12245000, BrazilDepartment of Microbiology, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Minas Gerais, BrazilEscola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, BrazilWeb of Science117-132engFuture sci ltdFuture Medicinal ChemistryAntimicrobialAuranofinBucillus SubtilisCandida AlbicansCryptococcus NeoformansEnterococcus FaecalisEnterococcus FaeciumStaphylococcus AureusCandida-AlbicansCryptococcus-NeoformansThioredoxin ReductaseRedox HomeostasisGlutathioneManagementViabilityMechanismSeleniumStressInhibition of bacterial and fungal pathogens by the orphaned drug auranofininfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/496162021-10-05 22:12:43.906metadata only accessoai:repositorio.unifesp.br:11600/49616Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652021-10-06T01:12:43Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.en.fl_str_mv Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin
title Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin
spellingShingle Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin
Fuchs, Beth Burgwyn
Antimicrobial
Auranofin
Bucillus Subtilis
Candida Albicans
Cryptococcus Neoformans
Enterococcus Faecalis
Enterococcus Faecium
Staphylococcus AureusCandida-Albicans
Cryptococcus-Neoformans
Thioredoxin Reductase
Redox Homeostasis
Glutathione
Management
Viability
Mechanism
Selenium
Stress
title_short Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin
title_full Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin
title_fullStr Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin
title_full_unstemmed Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin
title_sort Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin
author Fuchs, Beth Burgwyn
author_facet Fuchs, Beth Burgwyn
RajaMuthiah, Rajmohan
Souza, Ana Carolina Remondi [UNIFESP]
Eatemadpour, Soraya
Rossoni, Rodnei Dennis
Santos, Daniel Assis
Junqueira, Juliana C.
Rice, Louis B.
Mylonakis, Eleftherios
author_role author
author2 RajaMuthiah, Rajmohan
Souza, Ana Carolina Remondi [UNIFESP]
Eatemadpour, Soraya
Rossoni, Rodnei Dennis
Santos, Daniel Assis
Junqueira, Juliana C.
Rice, Louis B.
Mylonakis, Eleftherios
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Fuchs, Beth Burgwyn
RajaMuthiah, Rajmohan
Souza, Ana Carolina Remondi [UNIFESP]
Eatemadpour, Soraya
Rossoni, Rodnei Dennis
Santos, Daniel Assis
Junqueira, Juliana C.
Rice, Louis B.
Mylonakis, Eleftherios
dc.subject.eng.fl_str_mv Antimicrobial
Auranofin
Bucillus Subtilis
Candida Albicans
Cryptococcus Neoformans
Enterococcus Faecalis
Enterococcus Faecium
Staphylococcus AureusCandida-Albicans
Cryptococcus-Neoformans
Thioredoxin Reductase
Redox Homeostasis
Glutathione
Management
Viability
Mechanism
Selenium
Stress
topic Antimicrobial
Auranofin
Bucillus Subtilis
Candida Albicans
Cryptococcus Neoformans
Enterococcus Faecalis
Enterococcus Faecium
Staphylococcus AureusCandida-Albicans
Cryptococcus-Neoformans
Thioredoxin Reductase
Redox Homeostasis
Glutathione
Management
Viability
Mechanism
Selenium
Stress
description Background: We identified auranofin as an antimicrobial compound utilizing a high-throughput screen using a Caenorhabditis elegans-Staphylococcus aureus infection model. Results/methodology: Treatment of infected nematodes with auranofin resulted in a prolonged survival rate of 95%, reached with 0.78 mu g/ml. Further investigation of the antimicrobial activity of auranofin found inhibition against S. aureus, Enterococcus faecium and Enterococcus faecalis. Importantly, the fungal pathogens Cryptococcus neoformans was also effectively inhibited with an MIC at 0.5 mu g/ml. Auranofin appears to target the thioredoxin system. Conclusion: This work provides extensive additional data on the antibacterial effects of auranofin that includes both reference and clinical isolates and reports a novel inhibition of fungal pathogens by this compound.
publishDate 2016
dc.date.issued.fl_str_mv 2016
dc.date.accessioned.fl_str_mv 2019-01-21T10:30:09Z
dc.date.available.fl_str_mv 2019-01-21T10:30:09Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv Future Medicinal Chemistry. London, v. 8, n. 2, p. 117-132, 2016.
dc.identifier.uri.fl_str_mv http://repositorio.unifesp.br/handle/11600/49616
https://doi.org/10.4155/fmc.15.182
dc.identifier.issn.none.fl_str_mv 1756-8919
dc.identifier.doi.none.fl_str_mv 10.4155/fmc.15.182
dc.identifier.wos.none.fl_str_mv WOS:000369950000004
identifier_str_mv Future Medicinal Chemistry. London, v. 8, n. 2, p. 117-132, 2016.
1756-8919
10.4155/fmc.15.182
WOS:000369950000004
url http://repositorio.unifesp.br/handle/11600/49616
https://doi.org/10.4155/fmc.15.182
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.none.fl_str_mv Future Medicinal Chemistry
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 117-132
dc.publisher.none.fl_str_mv Future sci ltd
publisher.none.fl_str_mv Future sci ltd
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv
_version_ 1802764158599430144

Registros relacionados